681 related articles for article (PubMed ID: 23490332)
1. Outcomes and patterns of secondary relapse in platinum-sensitive ovarian cancer: implications for tertiary cytoreductive surgery.
Tang J; Liu DL; Shu S; Tian WJ; Liu Y; Zang RY
Eur J Surg Oncol; 2013 Jul; 39(7):786-91. PubMed ID: 23490332
[TBL] [Abstract][Full Text] [Related]
2. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
[TBL] [Abstract][Full Text] [Related]
3. Surgical cytoreduction for recurrent epithelial ovarian cancer.
Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
[TBL] [Abstract][Full Text] [Related]
4. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
Fan XM; Zhang J; Niu SH; Li KX; Song CZ
Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
[TBL] [Abstract][Full Text] [Related]
5. Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study.
van de Laar R; Zusterzeel PL; Van Gorp T; Buist MR; van Driel WJ; Gaarenstroom KN; Arts HJ; van Huisseling JC; Hermans RH; Pijnenborg JM; Schutter EM; Pelikan HM; Vollebergh JH; Engelen MJ; Inthout J; Kruitwagen RF; Massuger LF
BMC Cancer; 2014 Jan; 14():22. PubMed ID: 24422892
[TBL] [Abstract][Full Text] [Related]
6. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.
Petrillo M; Fagotti A; Ferrandina G; Fanfani F; Costantini B; Vizzielli G; Pedone Anchora L; Nero C; Margariti PA; Scambia G
Gynecol Oncol; 2013 Oct; 131(1):36-41. PubMed ID: 23791829
[TBL] [Abstract][Full Text] [Related]
8. Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer.
Felsinger M; Minar L; Weinberger V; Rovny I; Zlamal F; Bienertova-Vasku J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():154-160. PubMed ID: 29957400
[TBL] [Abstract][Full Text] [Related]
9. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy.
Matsumoto A; Higuchi T; Yura S; Mandai M; Kariya M; Takakura K; Fujii S
J Obstet Gynaecol Res; 2006 Dec; 32(6):580-7. PubMed ID: 17100820
[TBL] [Abstract][Full Text] [Related]
10. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?
Zang RY; Li ZT; Tang J; Cheng X; Cai SM; Zhang ZY; Teng NN
Cancer; 2004 Mar; 100(6):1152-61. PubMed ID: 15022281
[TBL] [Abstract][Full Text] [Related]
11. Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer: A multicentre MITO retrospective study.
Falcone F; Scambia G; Benedetti Panici P; Signorelli M; Cormio G; Giorda G; Bogliolo S; Marinaccio M; Ghezzi F; Rabaiotti E; Breda E; Casella G; Fanfani F; Di Donato V; Leone Roberti Maggiore U; Greggi S
Gynecol Oncol; 2017 Oct; 147(1):66-72. PubMed ID: 28716306
[TBL] [Abstract][Full Text] [Related]
12. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
[TBL] [Abstract][Full Text] [Related]
13. The Value of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer and Application of a Prognostic Score.
da Costa AA; Valadares CV; Mantoan H; Saito A; Salvadori MM; Guimarães AP; Sanches SM; Achatz MI; Baiocchi G
Int J Gynecol Cancer; 2016 Mar; 26(3):449-55. PubMed ID: 26825830
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
[TBL] [Abstract][Full Text] [Related]
15. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study.
Zang RY; Li ZT; Zhang ZY; Cai SM
Int J Gynecol Cancer; 2003; 13(4):419-27. PubMed ID: 12911717
[TBL] [Abstract][Full Text] [Related]
16. Preoperative factors predicting survival after secondary cytoreduction for recurrent ovarian cancer.
Frederick PJ; Ramirez PT; McQuinn L; Milam MR; Weber DM; Coleman RL; Gershenson DM; Landen CN
Int J Gynecol Cancer; 2011 Jul; 21(5):831-6. PubMed ID: 21613957
[TBL] [Abstract][Full Text] [Related]
17. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
18. The role of surgery in recurrent ovarian cancer.
Pfisterer J; Harter P; Canzler U; Richter B; Jackisch C; Hahmann M; Hasenburg A; Burges A; Loibl S; Gropp M; Huober J; Fink D; Bois A; ;
Int J Gynecol Cancer; 2005; 15 Suppl 3():195-8. PubMed ID: 16343230
[TBL] [Abstract][Full Text] [Related]
19. The clinical outcome of epithelial ovarian cancer patients with apparently isolated lymph node recurrence: a multicenter retrospective Italian study.
Gadducci A; Cosio S; Zola P; Sostegni B; Ferrero AM; Teti G; Cristofani R; Sartori E
Gynecol Oncol; 2010 Mar; 116(3):358-63. PubMed ID: 19954826
[TBL] [Abstract][Full Text] [Related]
20. Effect of radical cytoreductive surgery on omission and delay of chemotherapy for advanced-stage ovarian cancer.
Wright JD; Herzog TJ; Neugut AI; Burke WM; Lu YS; Lewin SN; Hershman DL
Obstet Gynecol; 2012 Oct; 120(4):871-81. PubMed ID: 22996105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]